ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
1Q 2023 ZYNLONTA®1 net sales increased
Implementing new go-to-market model to help drive growth in both academic and community centers
Later-stage pipeline programs continue to progress with several initial data readouts expected in the next 12-15 months and supported by cash runway to mid-2025
Portfolio prioritized to nearer-term clinical catalysts; reducing workforce by
Company to host conference call today at 8:30 a.m. EDT
LAUSANNE,
“2023 is a pivotal year for positioning ADC Therapeutics to capture the full potential value of our assets. Our later-stage pipeline programs continue to progress, with several initial data readouts expected in the next 12-15 months. Following a comprehensive review of the business by our executive team, we are implementing a new corporate and capital allocation strategy which we believe will allow the Company to focus on the most advanced and highest-potential clinical value drivers,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
“After a comprehensive DLBCL market review including interactions with top academic and community centers, we are implementing a new commercial go-to-market model to better align with the market construct. Through our new strategy, we expect to optimize our commercial execution against ZYNLONTA’s unique and valuable market opportunity,” said Kristen Harrington-Smith, Chief Commercial Officer of ADC Therapeutics.
“By focusing our resources and executing on our new portfolio and commercial strategy, I am confident that we will deliver on our objectives and unlock value for all of our stakeholders,” added Mr. Mallik.
(1) |
loncastuximab tesirine-lpyl; (2) |
Updated Corporate Strategy
Following a comprehensive assessment by the leadership team of the status of the business and the evolving market, the Company is adjusting its corporate strategy to optimize operations and prioritize potential key value drivers:
-
Implementing a new go-to-market model to help drive growth and optimize local area influence. The Company will continue to cover over
90% of the potential market opportunity with a team of account managers and community specialists that will foster tight coordination within referral networks and bring deep clinical and therapeutic experience. -
Re-prioritizing R&D pipeline to focus resources on the most advanced, lower risk value-generating programs:
-
The Company will continue the
LOTIS-5 ,LOTIS-9 andLOTIS-7 studies which, if successful and support future regulatory approvals, have the potential to significantly increase ZYNLONTA’s market opportunity in earlier lines of therapy and with multiple combination partners. - The Company will continue the clinical-stage programs: ADCT-601 targeting AXL, ADCT-901 targeting KAAG1, ADCT-602 targeting CD22.
- The Company will halt investments in its two preclinical programs ADCT-212 targeting PSMA and ADCT-701 targeting DLK-1.
-
The Company will continue the
-
Increasing efficiencies through a
17% workforce reduction driven primarily by functions affected by the portfolio prioritization and back-office efficiencies, while maintaining the customer-facing footprint. This reduction is effective today and includes full-time employees, vacant roles and contractors. Along with decreasing additional operating expenses, this will allow the Company to re-deploy capital in programs with the highest value-generating potential.
Recent Highlights and Developments
ZYNLONTA (loncastuximab tesirine-lpyl)
-
ZYNLONTA generated net sales of
$19.0 million 15% increase over first quarter of 2022 and a slight decline from fourth quarter 2022. This includes higher gross-to-net sales deductions due to Group Purchasing Organization (GPO) contracting and the new Medicare Part B discarded drug policy effective January 1, 2023. -
The pivotal Phase 2 clinical trial in
China , led by Overland ADCT BioPharma, achieved its primary objective and demonstrated efficacy and safety data consistent with prior clinical trial results. Based on these positive results, Overland ADCT BioPharma is preparing to submit its marketing authorization application to the China National Medical Products Administration (NMPA) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Pipeline
- ADCT-901 (targeting KAAG1): The Company is finalizing the protocol amendment to explore different dosing schedules to optimize the potential clinical outcomes for patients. Once finalized, the Company plans to advance to the next dosing level. The IHC assay is under final validation.
- ADCT-601 (targeting AXL): Dose escalation in the Phase 1b trial is progressing and a monotherapy cohort has been added for patients with non-small cell lung cancer (NSCLC) in addition to a monotherapy cohort focused on sarcoma. In parallel, the IHC assay is under final validation.
- ADCT-602 (targeting CD22): Dose escalation and expansion in the Phase 1 trial is progressing and the number of sites is being expanded.
- ADCT-212 (targeting PSMA): The Company is halting investments in this program to focus on nearer-term value drivers.
- ADCT-701 (targeting DLK-1): The Company is halting investments in this program to focus on nearer-term value drivers.
Guidance
The Company reaffirms the following guidance based on its current business plan:
-
ZYNLONTA FY 2023 net product sales expected to grow by a double-digit percentage year-over-year. This includes a gross-to-net increase as compared to 2022 of:
- Approximately 2 to 3 percentage points related to Group Purchasing Organization (GPO) contracting
- Mid to high single-digit percentage points resulting from the Infrastructure Investment and Jobs Act’s requirement for manufacturers of certain single-source drugs separately paid for under Medicare Part B and marketed in single-dose containers to provide annual refunds for discarded drug, effective January 1, 2023
- Continued decrease in total operating expenses expected in 2023 and 2024 as compared to 2022 as a result of the implementation of the new corporate strategy
- Expected cash runway extended into the middle of 2025
Upcoming Expected Milestones
ZYNLONTA
- Grow ZYNLONTA net sales by a double-digit percentage year-over-year and achieve commercial brand profitability in 2023
- European phased launch by partner Sobi beginning in 2Q 2023
-
Initial safety and efficacy data from the
LOTIS-9 study by the end of 2023 -
Complete enrollment of the
LOTIS-5 study in 2024 -
Initial safety and efficacy data from the
LOTIS-7 study in 2024
Pipeline
ADCT-901 (targeting KAAG1)
- Initial data from Phase 1 study in 1H 2024
ADCT-601 (targeting AXL)
- Initial data from Phase 1 study in 1H 2024
ADCT-602 (targeting CD22)
- Additional data from Phase 1 study in 1H 2024
First Quarter 2023 Financial Results
Cash and Cash Equivalents
Cash and cash equivalents were
Product Revenues
Net product revenues were
Research and Development (R&D) Expenses
R&D expenses were
Selling and Marketing (S&M) Expenses
S&M expenses were
General & Administrative Expenses
G&A expenses were
Net Loss and Adjusted Net Loss
Net loss was
Adjusted net loss was
The increase in net loss and adjusted net loss for the quarter ended March 31, 2023, as compared to the same quarter in 2022, was primarily due to license revenue of
Conference Call Details
ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events & Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Use of Non-IFRS Financial Measures
In addition to financial information prepared in accordance with IFRS, this document also contains certain non-IFRS financial measures based on management’s view of performance including:
- Adjusted net loss and income
- Adjusted net loss and income per share
Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-IFRS measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with IFRS. When preparing these supplemental non-IFRS measures, management typically excludes certain IFRS items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these IFRS items to be normal, recurring cash operating expenses; however, these items may not meet the IFRS definition of unusual or non-recurring items. Since non-IFRS financial measures do not have standardized definitions and meanings, they may differ from the non-IFRS financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other IFRS financial measures.
The following items are excluded from adjusted net loss and adjusted net loss per share:
Shared-Based Compensation Expense: We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
Certain Other Items: We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be: changes in the fair value of derivatives and warrant obligations and the effective interest expense associated with the Facility Agreement with
See the attached Reconciliation of IFRS Measures to Non-IFRS Measures for explanations of the amounts excluded and included to arrive at the non-IFRS financial measures.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the 2023 net product sales guidance for ZYNLONTA® and the decrease in total operating expenses for 2023 and 2024, the expected cash runway into the middle of 2025, the effectiveness of the new commercial go-to-market strategy and the Company’s ability to continue to commercialize ZYNLONTA® in
ADC Therapeutics SA Condensed Consolidated Interim Statement of Operations (Unaudited) (in KUSD except for per share data) |
||||||
|
|
For the Three Months Ended
|
||||
|
|
2023 |
|
2022 |
||
Product revenues, net |
|
18,953 |
|
|
16,498 |
|
License revenues and royalties |
|
39 |
|
|
30,000 |
|
Total revenue |
|
18,992 |
|
|
46,498 |
|
|
|
|
|
|
||
Operating expense |
|
|
|
|
||
Cost of product sales |
|
(590 |
) |
|
(529 |
) |
Research and development expenses |
|
(39,480 |
) |
|
(48,952 |
) |
Selling and marketing expenses |
|
(15,351 |
) |
|
(18,370 |
) |
General and administrative expenses |
|
(15,143 |
) |
|
(19,011 |
) |
Total operating expense |
|
(70,564 |
) |
|
(86,862 |
) |
Loss from operations |
|
(51,572 |
) |
|
(40,364 |
) |
|
|
|
|
|
||
Other income (expense) |
|
|
|
|
||
Financial income |
|
2,304 |
|
|
18,308 |
|
Financial expense |
|
(10,417 |
) |
|
(9,217 |
) |
Non-operating (expense) income |
|
(3 |
) |
|
13,442 |
|
Total other (expense) income |
|
(8,116 |
) |
|
22,533 |
|
Loss before taxes |
|
(59,688 |
) |
|
(17,831 |
) |
Income tax benefit |
|
262 |
|
|
1,170 |
|
Net loss |
|
(59,426 |
) |
|
(16,661 |
) |
|
|
|
|
|
||
Net loss attributable to: |
|
|
|
|
||
Owners of the parent |
|
(59,426 |
) |
|
(16,661 |
) |
|
|
|
|
|
||
Net loss per share, basic and diluted |
|
(0.74 |
) |
|
(0.22 |
) |
ADC Therapeutics SA Condensed Consolidated Interim Balance Sheet (Unaudited) (in KUSD) |
||||||
|
|
March 31,
|
|
December 31,
|
||
ASSETS |
|
|
|
|
||
Current assets |
|
|
|
|
||
Cash and cash equivalents |
|
310,547 |
|
|
326,441 |
|
Accounts receivable, net |
|
24,037 |
|
|
72,971 |
|
Inventory |
|
18,250 |
|
|
18,564 |
|
Other current assets |
|
27,173 |
|
|
28,039 |
|
Total current assets |
|
380,007 |
|
|
446,015 |
|
Non-current assets |
|
|
|
|
||
Property, plant and equipment |
|
4,484 |
|
|
3,261 |
|
Right-of-use assets |
|
11,224 |
|
|
6,720 |
|
Intangible assets |
|
13,586 |
|
|
14,360 |
|
Interest in joint venture |
|
29,533 |
|
|
31,152 |
|
Deferred tax asset |
|
27,605 |
|
|
26,757 |
|
Other long-term assets |
|
1,233 |
|
|
903 |
|
Total non-current assets |
|
87,665 |
|
|
83,153 |
|
|
|
|
|
|
||
Total assets |
|
467,672 |
|
|
529,168 |
|
|
|
|
|
|
||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
||
Current liabilities |
|
|
|
|
||
Accounts payable |
|
8,694 |
|
|
12,351 |
|
Other current liabilities |
|
57,412 |
|
|
73,035 |
|
Lease liabilities, short-term |
|
1,447 |
|
|
1,097 |
|
Senior secured term loans, short-term |
|
13,533 |
|
|
12,474 |
|
Total current liabilities |
|
81,086 |
|
|
98,957 |
|
Non-current liabilities |
|
|
|
|
||
Senior secured term loans, long- term |
|
97,011 |
|
|
97,240 |
|
Warrant obligations |
|
516 |
|
|
1,788 |
|
Deferred royalty obligation, long-term |
|
216,551 |
|
|
212,353 |
|
Deferred gain of joint venture |
|
23,539 |
|
|
23,539 |
|
Lease liabilities, long-term |
|
10,955 |
|
|
6,564 |
|
Other long-term liabilities |
|
329 |
|
|
— |
|
Total non-current liabilities |
|
348,901 |
|
|
341,484 |
|
|
|
|
|
|
||
Total liabilities |
|
429,987 |
|
|
440,441 |
|
|
|
|
|
|
||
Equity attributable to owners of the parent |
|
|
|
|
||
Share capital |
|
7,312 |
|
|
7,312 |
|
Share premium |
|
1,007,843 |
|
|
1,007,452 |
|
Treasury shares |
|
(645 |
) |
|
(679 |
) |
Other reserves |
|
163,501 |
|
|
155,683 |
|
Cumulative translation adjustments |
|
(215 |
) |
|
(356 |
) |
Accumulated losses |
|
(1,140,111 |
) |
|
(1,080,685 |
) |
Total equity attributable to owners of the parent |
|
37,685 |
|
|
88,727 |
|
|
|
|
|
|
||
Total liabilities and equity |
|
467,672 |
|
|
529,168 |
|
ADC Therapeutics SA Reconciliation of IFRS Measures to Non-IFRS Measures (Unaudited) (in KUSD except for share and per share data) |
||||||
|
Three Months Ended
|
|||||
in KUSD (except for share and per share data) |
2023 |
|
2022 |
|||
Net loss |
(59,426 |
) |
|
(16,661 |
) |
|
Adjustments: |
|
|
|
|||
Share-based compensation expense (i) |
8,074 |
|
|
13,910 |
|
|
Convertible loans, derivatives, change in fair value income (ii) |
— |
|
|
(15,855 |
) |
|
Senior secured term loans, warrants, change in fair value income (ii) |
(656 |
) |
|
— |
|
|
Effective interest expense on convertible loans (iii) |
— |
|
|
3,022 |
|
|
|
(616 |
) |
|
— |
|
|
Effective interest expense on senior secured term loan facility (iii) |
4,540 |
|
|
— |
|
|
Deferred royalty obligation interest expense (iv) |
5,746 |
|
|
6,142 |
|
|
Deferred royalty obligation cumulative catch-up adjustment income (iv) |
(129 |
) |
|
(18,288 |
) |
|
Adjusted net loss |
(42,467 |
) |
|
(27,730 |
) |
|
|
|
|
|
|||
Net loss per share, basic and diluted |
(0.74 |
) |
|
(0.22 |
) |
|
Adjustment to net loss per share, basic and diluted |
0.21 |
|
|
(0.14 |
) |
|
Adjusted net loss per share, basic and diluted |
(0.53 |
) |
|
(0.36 |
) |
|
Weighted average shares outstanding, basic and diluted |
80,805,770 |
|
|
76,821,726 |
||
(i) |
Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted, including any market and other performance conditions, and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These accounting entries have no cash impact. |
|
|
||
(ii) |
Change in the fair value of the convertible loan derivatives, senior secured term loan facility warrants and the |
|
(iii) |
Effective interest expense on convertible loans and senior secured term loans relates to the increase in the value of our loans in accordance with the amortized cost method. |
|
(iv) |
Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustment income relates to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005395/en/
Investors
Eugenia Litz
ADC Therapeutics
Eugenia.Litz@adctherapeutics.com
+44 7879 627205
+1 908-723-2350
Amanda Loshbaugh
ADC Therapeutics
amanda.loshbaugh@adctherapeutics.com
+1 917-288-7023
Media
Mary Ann Ondish
ADC Therapeutics
maryann.ondish@adctherapeutics.com
+1 914-552-4625
Source: ADC Therapeutics SA
